Zevra Therapeutics’ MIPLYFFA receives FDA approval as first treatment for Niemann-Pick disease
Zevra Therapeutics Inc. has announced U.S. Food and Drug Administration (FDA) approval of MIPLYFFA (arimoclomol), a capsule-based treatment for Niemann-Pick disease type C (NPC), a ... Read More
Amplia Therapeutics secures FDA fast track status for narmafotinib in pancreatic cancer, stock surges
Amplia Therapeutics Limited (ASX: ATX) has announced that its Focal Adhesion Kinase (FAK) inhibitor, narmafotinib, has been granted Fast Track Designation by the United States ... Read More
AstraZeneca withdraws COVID-19 vaccine amid legal challenges and commercial decisions
In a significant development, UK-based pharmaceutical giant AstraZeneca has announced the global withdrawal of its COVID-19 vaccine, known as Covishield in India and Vaxzevria in ... Read More
Roche to strengthen gene therapy portfolio with Spark Therapeutics acquisition
Swiss pharmaceutical giant Roche has reached a major agreement to acquire the U.S.-based gene therapy company Spark Therapeutics in an all-cash deal valued at $4.3 ... Read More